Allelica, the leader in polygenic risk scoring, is expanding its Scientific Advisory Committee

Four experts from leading medical and academic institutions in the United States to advise on strategies for clinical implementation of Allelica’s Polygenic Risk Score (PRS), a predictive tool for determining patients with high genetic susceptibility to breast cancer, prostate cancer, coronary artery disease, Alzheimer’s and type 2- diabetes.

NEW YORK, February 3, 2022 / PRNewswire / – Allelica leading genomics software company that develops polygenic risk scores (PRS) for Common Diseases, has expanded its Scientific Advisory Committee with the addition of four U.S.-based experts in genomics, cardiology, and oncology. Each of these scientists has made significant contributions to the development of genomic medicine.

Allelica's PREDICT module is a resource for clinical laboratories and healthcare providers to build personal PRS reports for a range of complex diseases.

“Allelica is focused on promoting the clinical integration of Allelica’s PRS software into healthcare systems and giving patients access to precision medicine,” said Giordano Bottà, PhD, CEO of Allelica. “We are pleased to welcome four leading scientists in their respective fields to help guide Allelica in our mission to promote disease prevention through wider use of polygenic risk scores in healthcare.”

Each of the four scientists brings a unique perspective on how PRS can equip healthcare providers and clinical laboratories with cutting-edge tools to reduce the impact of common disease through genomic medicine:

  • Noura S. Abul-HusnMD, PHD is the founding head of the Department of Genomic Medicine at the Department of Medicine and the clinical director of the Department of Genomic Health at the Icahn School of Medicine at. Sinai Mountain. She is an associate professor of medicine and genetics and board certified in internal medicine and medical genetics. Dr. Abul-Husn is an expert in utilizing large-scale genomic data linked to electronic health records.

  • Robert C. GreenMD, MPH is a professor of medicine (genetics) at Harvard Medical School and a medical scientist leading the G2P (Genomes 2 People) Research Program at Brigham and Women’s Hospital, Broad Institute, and Ariadne Labs. Dr. Green is internationally recognized for research and policy efforts aimed at accelerating the implementation of genomic and precision medicine.

  • Gordon S. HugginsMD is Director of the Molecular Cardiology Research Institute (MCRI) Center for Translational Pharmacology and Genomics, Associate Professor at Tufts University School of Medicine, and a practicing cardiologist. He led the genetic auxiliary study for the Look AHEAD study, led the NHLBI Heart Failure Network program at 6 p.m. Totter and directed participation in the Dilated Cardiomyopathy Genetics Consortium. His research interest is focused on making scientific discoveries relevant to human diseases that can be translated into new biomarkers or therapies.

  • Aleksandar RajkovicMD, PhD, is UCSF’s chief genomics officer, professor of pathology and medical director and head of the Center for Genetic and Genomic Medicine in the UCSF Health System. Prior to his position at UCSF, he was Head of Medical and Laboratory Genetics at University of Pittsburgh Medical center, where he supervised Pittsburgh molecular genomic laboratories as well as clinical services for adults / cancer.

In addition to these US-based experts, Allelica’s international advisory committee includes PRS pioneers, Professor Bjarni Vilhjálmsson, from Denmark. Bjarni is one of the most cited scientists in the development of PRS methods and has made major contributions to the promotion of PRS through the development of LD-pred and other calculation methods.

Further information on Allelica’s advisors and management team can be found at the company’s website.

What is a polygenic risk score?
A PRS is a measure of a person’s risk of disease based on their genes and is based on combining the effects of many genetic variants across the genome. This information can be used to stratify individuals based on their risk of disease. By combining PRS with conventional risk factors, Allelica aims to make precision medicine available on a large scale.

About Allelica
Allelica is a leading genomic software company specializing in secure and scalable solutions for implementing clinical degree of polygenic risk score (PRS). Allelica’s technology combines world-class data sets with the most advanced algorithms to build PRSs with the highest predictive power to estimate disease risk. Allelica’s tools translate the enormous potential of genomic data into practical tools that can be used to identify individuals with a high genetic susceptibility to life-threatening diseases. By incorporating genetics into disease risk assessments, Allelica helps build the foundation for preventative medicine by helping identify those for whom early intervention and behavioral changes can help reduce lifetime risk. Allelica has a partnership with Merck to develop a range of tools for the prevention of cardiovascular disease. To learn more, visit

Allelica enables the next generation of clinical genomics

See original content for downloading multimedia:

SOURCE Allelica Inc.

Leave a Comment

%d bloggers like this: